Hims, Apostrophe and dermatology
Hims & Hers to Discontinue Dermatology Line Apostrophe
Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology products and operations into one seamless experience,” Hims & Hers said.
Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...
Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...
Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...
Shares of Hims & Hers Health ( HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its ...
Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Discover why Hims & Hers faces steep corrections amid GLP-1 headwinds and valuation concerns, despite promising FY2024 growth ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration ...
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback